Replies to post #193697 on Biotech Values

[dewophile]

I see 8 weeks treatments as quite possible based on 100% cure rates G-1

do we know the 8 week arm had 100% SVR from today's cc? if so i would think they would at least probe a 6 week regimen in ph 2

[DewDiligence]

ABBV/ENTA—I am a little curious why there has been no data release of [GT2/GT3] for 2nd gen program. If the G-3 data is as good as the G-1...

In all likelihood, the phase-2 GT3 data do not show a 100% SVR; however, even a number as “low” as 90% in GT3 is probably sufficient to market the ABT-493/ABT-530 regimen as pan-genotypic. We’ll get the full story at AASLD.